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The function of the epidermal growth factor receptor (EGFR) family member HER4 remains unclear
because its activating ligand, heregulin, results in either proliferation or differentiation. This variable response
may stem from the range of signals generated by HER4 homodimers versus heterodimeric complexes with
other EGFR family members. The ratio of homo- and heterodimeric complexes may be influenced both by a
cell’s EGFR family member expression profile and by the ligand or even ligand isoform used. To define the role
of HER4 in mediating antiproliferative and differentiation responses, human breast cancer cell lines were
screened for responses to heregulin. Only cells that expressed HER4 exhibited heregulin-dependent anti-
proliferative responses. In-depth studies of one line, SUM44, demonstrated that the antiproliferative and
differentiation responses correlated with HER4 activation and were abolished by stable expression of a
kinase-inactive HER4. HB-EGF, a HER4-specific ligand in this EGFR-negative cell line, also induced an
antiproliferative response. Moreover, introduction and stable expression of HER4 in HER4-negative SUM102
cells resulted in the acquisition of a heregulin-dependent antiproliferative response, associated with increases
in markers of differentiation. The role of HER2 in these heregulin-dependent responses was examined through
elimination of cell surface HER2 signaling by stable expression of a single-chain anti-HER2 antibody that
sequestered HER2 in the endoplasmic reticulum. In the cell lines with either endogenously (SUM44) or
exogenously (SUM102) expressed HER4, elimination of HER2 did not alter HER4-dependent decreases in cell
growth. These results suggest that HER4 is both necessary and sufficient to trigger an antiproliferative response
in human breast cancer cells.
The epidermal growth factor receptor (EGFR) family has
been implicated in breast cancer pathogenesis and progression
(reviewed in references 13 and 39). Aberrant expression of at
least two of the family members, EGFR and HER2, has been
associated with poor prognosis and differential response to
therapy (21, 28, 31, 44). Recently, treatment targeted against
HER2 has demonstrated clinical efficacy, emphasizing the im-
portance of members of this receptor family in breast cancer
prognosis and therapy (10).
The EGFR family consists of four known members: EGFR
(HER1, erbB-1), HER2 (erbB-2), HER3 (erbB-3), and HER4
(erbB-4) (reviewed in references 13, 34, and 39). The four
receptors form homodimers or heterodimers upon activation
by two sets of ligands, the EGF and heregulin/neuregulin fam-
ilies. There are several possible hetero- and homodimeric re-
ceptor combinations, which theoretically result in differential
activation of multiple downstream signal transduction path-
ways. Additional heterogeneity results from varying pheno-
typic responses, depending on cell type and the duration or
intensity of downstream signaling, determined in part by dif-
ferences in ligand affinity, recycling, and intracellular environ-
ment, as well as other factors that govern the turnover of
receptor family members (53). Because of this complexity, our
understanding of EGFR family member biology is still rela-
tively rudimentary, despite the clinical utility of biologic mod-
ifiers of EGFR and HER2.
The EGFR family members share structural and sequence
similarity; there are, however, critical differences. HER2 has
no known directly binding ligand but is the favored het-
erodimerization partner of each ligand-bound family member
(50). HER3 has no significant kinase activity, unlike the other
family members, but contains multiple phosphatidylinositol
3-kinase binding motifs that are phosphorylated by a het-
erodimeric kinase-active partner (20, 45). HER4 is more sim-
ilar to EGFR and HER2 than to HER3, but it does contain a
canonical phosphatidylinositol 3-kinase binding motif (14).
Unlike EGFR and HER2, which have been associated with
more aggressive clinical breast cancers, in several case series
HER4 expression was correlated with low proliferative index
and estrogen receptor expression, suggesting that HER4 may
have a different impact on breast biology and cancer.
Heregulin, or Neu differentiating factor, is a member of a
complex ligand family that was initially thought to be the long-
sought HER2 ligand but was ultimately shown to activate
HER2 through heterodimerization after binding to HER3 or
HER4 (2, 7, 23, 33, 36, 54). Heregulin was also identified as a
factor that caused differentiation in MDA-MB-453 human
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breast cancer cells (11), but its biologic effect, proliferation or
differentiation, differed depending upon the cell lines used
during its purification, hence the two names (heregulin and
Neu differentiating factor). Subsequent work by many groups
has shown that heregulin is expressed as multiple isoforms
(reviewed in reference 34). Heregulin a, b 1, b 2, and b 3 were
cloned, and heregulin b1 was shown to cause tyrosine phos-
phorylation of p185 HER2 (23). Heregulin b3 is a soluble form
of heregulin, while other isoforms are at least initially mem-
brane bound (54). A second genetic locus encodes neuregu-
lin-2, which also causes MDA-MB-453 morphologic change
but with less potency and less HER2 phosphorylation (7, 8). In
general, heregulin isoforms have variable potency and receptor
specificity. Heregulin a and b have different effects on mouse
mammary development (26). Neuregulin 2 binds to HER3 and
HER4, but there is a newly discovered third gene whose prod-
uct, neuregulin 3, thus far has been found to bind to HER4
alone (56). Recently, neuregulin 4 has been identified (22).
The cell-type-specific effects of heregulin-induced prolifera-
tion or differentiation may be related to the expression, acti-
vation, and level of HER2, HER3, or HER4. Because heregu-
lin causes HER2 tyrosine phosphorylation indirectly through
its binding to HER3 and HER4, the ligand could mediate its
differentiative or proliferative signal singly through HER4 or
through complexes containing combinations of HER2, HER3,
and HER4 (33). With this complexity of potency, receptor
specificity, tissue distribution, and soluble or membrane-bound
isoforms, it is not surprising that different experimental results
have been obtained using different cells or isoforms. The b2
isoform of heregulin caused differentiation in MDA453 cells
(1). However, the b3 isoform proved to be mitogenic in the
same cell line (5). Others have demonstrated a differentiation
response using the b1 isoform (9, 35). In addition, the response
has been shown to be concentration dependent. In AU565 and
MDA-MB-453 cells a low concentration of heregulin is mito-
genic, whereas a higher concentration leads to differentiation
and inhibition of cell growth (2). There are also differences in
response to heregulin depending on the receptor density. In a
panel of human breast cancer cell lines, level of expression of
HER2 correlated with response to heregulin; cells expressing
low levels of HER2 had mitogenic responses to heregulin,
while cells expressing high levels of HER2 had differentiation
responses (12, 17, 42). Response also depends on the cell line
used and the amount of serum in the medium, as expected due
to heterogenous expression of receptors and ligand (27).
HER4 can also be activated by another complex family of
ligands—the EGF family. Like the heregulins, there is consid-
erable variability in receptor activation and potency. Heparin-
binding EGF (HB-EGF) binds to EGFR and HER4 (15) and
induces HER4 phosphorylation in MDA-MB-453 cells. Beta-
cellulin also binds EGFR and HER4 but not other EGFR
family members (5, 37). Epiregulin activates all four EGFR
family members and, in MDA-MB-453 cells (which lack ap-
preciable EGFR), causes a differentiated phenotype (25, 38,
43). Affinity labeling and competition experiments demon-
strate that epiregulin binds cooperatively to HER2-HER4, but
not to HER3-HER4, heterodimers and directly binds EGFR
and HER4.
Because HER4 appears to be associated with better prog-
nostic features and can be activated by differentiation-inducing
ligands, we attempted to clarify the role of HER4 by asking
whether HER4 alone was necessary and sufficient to transmit
an antiproliferative signal. We determined that HER4 activa-
tion by a member of the heregulin or the EGF family could
transmit an antiproliferative response, and that expression of
HER4 in a HER4-negative cell line was sufficient to confer an
antiproliferative response. Perhaps most intriguingly, elimina-
tion of HER2 signaling did not abolish HER4-dependent an-
tiproliferative responses in at least two distinct cell lines.
MATERIALS AND METHODS
Cell lines, tissue culture, and antibodies. SUM44 and SUM102 cells were
grown in serum-free growth factor-defined media as previously described (16,
41). SUM102 cells were derived from a microinvasive primary breast tumor,
whereas SUM44 cells were derived from a metastatic pleural effusion. MDA-
MB-453 cells were obtained from the American Type Culture Collection and
were grown in Dulbecco modified Eagle medium supplemented with 10% fetal
bovine serum. All cells were grown in a humidified incubator at 37°C with 10%
CO2 and subcultured weekly, and the medium was changed three times per week.
All tissue medium reagents were obtained from Sigma, except for fetal bovine
serum and insulin, which were obtained from Gibco BRL.
Proliferation assays. Cells were plated into six-well plates at a density of 5 3
104 to 5 3 105 cells per well and grown in the appropriate medium with or
without recombinant heregulin b1 (gift from Amgen) or HB-EGF (R&D) for 6
to 7 days, or three medium changes. Cells were trypsinized and counted with a
hemocytometer.
Quantitative PCR. Total RNA was isolated using the guanidinium isothiocya-
nate-based RNeasy kit (Qiagen) and was treated with RNAse-free DNAse (Am-
bion) to prevent nonspecific priming of the PCRs. HER4-specific 59-39 oligonu-
cleotides and an intervening fluorescent dye-labeled probe were designed using
Primer Express software (ABI/Perkin Elmer). The nonextendable HER4 probe
was synthesized and labeled with 59 FAM (6-carboxyfluorescein) reporter and 39
TAMRA (6-carboxy-tetramethyl-rhodamine) quencher dyes (Integrated DNA
Technologies), followed by high-pressure liquid chromatography purification.
Real-time fluorescence quantitative PCR was performed with the ABI PRISM
7700 (PE Bio). Full-length HER4 mRNA was in vitro transcribed using ME-
GAscript (Ambion) and used as a positive control and absolute quantitation
standard for the assays. Similarly transcribed constructs for HER1, HER2, and
HER3 were used as negative controls. Amplifications of twofold serial dilutions
of full-length HER4 RNA were used to construct standard linear curves that
permit us to routinely and accurately measure from 200 copies to 90 million
template copies of HER4 mRNA. Ten nanograms of total RNA isolated from
the cell lines was assayed in triplicate for HER4 expression levels.
Immunoprecipitation and immunoblot analysis. Cells were washed with cold
phosphate-buffered saline and lysed in lysis buffer containing 20 mM HEPES
(pH 7.3), 50 mM sodium fluoride, 10% glycerol, 1% Triton X-100, 5 mM EDTA,
and 0.5 M NaCl supplemented with the tyrosine phosphatase inhibitor sodium
orthovanadate (1 mM) and the protease inhibitors aprotinin(6 mg/ml) and leu-
peptin(10 mg/ml). Nuclei and insoluble material were removed by centrifugation
at 13,000 3 g for 10 min at 4°C. Receptor proteins were precipitated with various
antibodies [HER2, clone 9G6.10, mouse monoclonal antibody (Neomarkers,
Inc.); HER3, (c-17)G, goat polyclonal antibody (Santa Cruz); HER4, polyclonal
rabbit antisera raised against recombinant gluthathione S-transferase fusion pro-
tein containing the C-terminal 80 amino acids of HER4] and protein A/G or
protein A agarose beads (Santa Cruz) for 3 h at 4°C. Immune complexes were
washed three times with lysis buffer and denatured in sodium dodecyl sulfate
sample buffer. Protein samples were separated on a sodium dodecyl sulfate–8%
polyacrylamide gel electrophoresis gel and were electrophoretically transferred
to a Sequi-blot polyvinylidene difluoride membrane (Bio-Rad). After blocking
with 3% cold fish gelatin (Sigma), the membrane was probed overnight at 4°C
with antiphosphotyrosine antibody (RC20; Transduction Laboratories), washed
three times with Tris-buffered saline–Tween, and detected with an enhanced
chemiluminescence detection kit (Amersham Life Sciences).
Neutral lipid detection. Cells were grown on glass coverslips in appropriate
media with or without heregulin or HB-EGF for 1 week and then fixed with 10%
neutral buffered formalin for 10 min. After a 60% isopropyl alcohol rinse, they
were stained with Sudan IV solution (10 g of Sudan IV, 500 ml of acetone, 500
ml of 70% ethyl alcohol) for 4 min, followed by 60% isopropyl alcohol and
distilled water rinses. Cells were then stained with Gill’s hematoxylin (Fisher
Scientific) for 1 min, rinsed in distilled water, and then stained with lithium
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FIG. 1. (A) Proliferative response of human breast cancer cell lines to heregulin. Cells were plated at a density of 5 3 104 to 5 3 105 cells per
well, depending on plating efficiency and growth rate, in six-well plates and grown in the presence or absence of 10 ng of heregulin b1 per ml for
three medium changes (7 days; approximately three doublings), and the number of cells was counted. The ratio of number of cells grown in the
presence versus the absence of heregulin is shown, with the number of cells (average of three experiments) listed at the top of each column. Error
bars represent standard deviations of at least three experiments. SUM185 (P 5 0.03), SUM225 (P 5 0.03), and SUM44 (P 5 0.0009) cells
demonstrated a statistically significant (by Student’s t test) heregulin-dependent antiproliferative effect, with the effect in SUM44 cells being most
pronounced. (B) HER4 mRNA levels as determined by quantitative PCR. Total RNA was extracted and reverse transcribed, and quantitative PCR
was performed with the ABI PRISM 7700 using HER4-specific fluorescence-labeled oligonucleotide probes, as described in Materials and Methods.
(C) HER1, -2, and -3 mRNA levels as determined by quantitative PCR. Quantitative PCR was performed using HER1-, HER2-, and HER3-
specific probes as described above. The abundance of message of the other EGFR family members is usually much higher than that of HER4.
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carbonate (47 g of lithium carbonate, 3,500 ml of distilled water) till blue (about
30 s). After thorough rinsing in distilled water, slides were mounted in Aqua-
mount for direct microscopic visualization of red-staining lipid droplets. Alter-
natively, staining of neutral lipid droplets in the cellular cytoplasm was done as
described previously (40). In brief, the cells suspended in phosphate-buffered
saline (106 cells/ml) were incubated for 5 min with Nile red (final concentration,
100 ng/ml) at room temperature. The yellow fluorescence of Nile red-stained
neutral lipids droplets was analyzed with a FACScan (Becton Dickinson) using
linear amplifiers.
cDNA constructs and clones. Full-length human HER4 cDNA was created
from three PCR fragments amplified from MDA-MB-453 cells. The fragments
were recombined into the pLXSN retroviral vector (29), and the resulting full-
length cDNA was sequenced in its entirety. The kinase-dead HER4 construct
was created by site-directed mutagenesis, changing lysine to alanine in the 751
position and abolishing the ability to bind ATP. The construct was entirely
sequenced and cloned into pLXSN. The 5R construct is a HER2 single-chain
antibody with an endoplasmic reticulum (ER)-targeting sequence cloned into the
pBABEpuro vector (19).
Creation of cell lines stably expressing introduced constructs. For production
of retrovirus using the above cDNAs in pLXSN, the amphotropic packaging cell
line PA317 was plated at 5 3 105 cells per 60-mm dish and then transfected with
20 mg of retroviral DNA using 2 M CaCl2 precipitation as previously described
(32). Viral supernatants were collected after 60 h of incubation, the last 48 h at
37°C with addition of sodium butyrate as described previously (30). Viral super-
natants were filtered through a 0.45-mm-pore-size syringe filter, and 1 ml of viral
supernatant was added with 8 mg of Polybrene per ml to recipient cells which had
been plated at 7 3 105 cells per 100-mm dish the day before. After 48 h of
incubation, cells were placed in medium containing G418 (0.3 mg/ml for
SUM102 and 0.5 mg/ml for SUM44). G418-resistant, puromycin-resistant, or
G418- and puromycin-resistant cells were pooled, and expression of the cDNA
product was confirmed by Western blotting or reverse transcription-PCR (RT-
PCR).
RESULTS
Proliferative response of human breast cancer cell lines to
heregulin. Heregulin has been shown to cause alternatively a
mitogenic or an antimitogenic effect under various experimen-
tal conditions. To determine the range of this effect, and to
select appropriate cell lines for study of the differentiative
effects of heregulin, we characterized the proliferative re-
sponse to heregulin of a panel of human breast cancer cell
lines, many of which had not previously been evaluated for
their heregulin response. The cell lines differ in their EGFR
family member expression (Fig. 1B and C) and their exogenous
ligand requirements. Many grow under growth factor-defined,
serum-free conditions, allowing evaluation of the effect of
heregulin without the confounding factor of undefined serum
growth factors and without subjecting the cells to serum star-
vation. Three cell lines demonstrated a significant growth in-
hibitory response to heregulin: SUM44, SUM185, and SUM225
(Fig. 1A). The MDA-MB-453 cells obtained from the Ameri-
can Type Culture Collection were only minimally responsive to
heregulin and in fact grew slowly under the conditions tested.
As discussed below, they appeared to have constitutive activa-
tion of HER4, which precluded their use for evaluation of
ligand dependence. MCF10A cells, which have been shown to
have a proliferative response to heregulin when grown in se-
rum-containing medium or when starved of insulin or EGF,
did not demonstrate a proliferative effect when heregulin was
added to defined medium containing EGF and insulin.
To correlate the antiproliferative response with HER4 ex-
pression, mRNA levels from these cell lines were evaluated by
quantitative PCR using the ABI PRISM 7700 (Fig. 1B and C).
The three cell lines that demonstrated an antiproliferative re-
sponse to heregulin all expressed HER4, while the cell lines
that lacked an antiproliferative response to heregulin did not,
or expressed very low levels. Thus, HER4 expression corre-
lated with an antiproliferative response to heregulin.
Receptor tyrosine phosphorylation in response to heregulin
stimulation. Previous work (1) led us to examine heregulin-
dependent tyrosine phosphorylation of the EGFR family mem-
bers in MDA-MB-435 cells, which have a high level of HER2
expression (Fig. 1C) and modest HER4 mRNA levels as mea-
sured by quantitative PCR. Despite low levels of HER4 mes-
sage, substantial, constitutive HER4 tyrosine phosphorylation
was observed, which was not further increased by heregulin
treatment (Fig. 2A). In contrast, the low-level constitutive
HER2 tyrosine phosphorylation was further induced by heregu-
FIG. 2. Receptor tyrosine phosphorylation in response to heregulin
stimulation. Cells were treated with 10 ng of heregulin b1 or 100 ng of
HB-EGF per ml for 30 min or left untreated. Cell lysates were immu-
noprecipitated (IP) with antibodies to HER2, HER3, or HER4 and
immunoblotted with antiphosphotyrosine (anti-PY) antibody RC20.
(A) Heregulin induced tyrosine phosphorylation of HER2 in MDA-
MB-453 cells, but these cells demonstrated constitutively phosphory-
lated HER4, which was not further induced by heregulin. (B) Heregu-
lin induced tyrosine phosphorylation of HER2, HER3, and HER4 but
HB-EGF induced tyrosine phosphorylation of only HER4 in SUM44
cells. (C) Antiproliferative response to HB-EGF. SUM44 cells were
plated at a density of 5 3 105 cells per well in six-well plates and grown
in the presence or absence of 10 ng of heregulin B1 or 100 ng of
HB-EGF per ml for three medium changes (7 days), and the number
of cells was counted. The ratio of number of cells grown in the pres-
ence versus the absence of ligand is shown. Error bars represent
standard deviations of at least three experiments. Like heregulin, HB-
EGF caused a significant antiproliferative effect, although the effect of
HB-EGF was not as great as that of heregulin.
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lin. Thus, any antiproliferative effect mediated by HER4 was
already near the maximum, and in fact this clone of MDA-
MB-453 cells proliferates slowly even in the absence of heregu-
lin, displaying the flattened morphology with prominent vacu-
olization and the high cytoplasm-to-nucleus ratio typical of the
differentiated phenotype described for MDA-MB-453 cells.
Therefore, despite clear induction of HER2 phosphorylation
by heregulin, there was no positive or negative proliferative
change, and this clone was not useful for ligand-dependent
studies.
In contrast, SUM44 cells demonstrated a consistent antipro-
liferative response to heregulin. Without heregulin treatment
there was no HER2 or HER4 activation (Fig. 2B). As antici-
pated, since it is a ligand for both HER3 and HER4 that can
also dimerize with and activate HER2, heregulin induced ty-
rosine phosphorylation of HER2, HER3, and HER4.
HER4 tyrosine phosphorylation and antiproliferative re-
sponse to HB-EGF. Since heregulin induces HER2, HER3,
and HER4 tyrosine phosphorylation, any or all could be re-
sponsible for the antiproliferative response. Therefore, the ef-
fect of a ligand that would bind specifically to HER4 was
examined. HB-EGF binds to EGFR and HER4 but not di-
rectly to HER2 or HER3 (15). As anticipated, when SUM44
cells were treated with HB-EGF, HER4 became tyrosine phos-
phorylated, but, in contrast to results with heregulin, HER2
and HER3 were not (Fig. 2B). SUM44 cells do not express
EGFR. HB-EGF-induced HER4 tyrosine phosphorylation was
not as robust as that resulting from heregulin stimulation. The
consequence of HB-EGF-dependent HER4 tyrosine phos-
phorylation in SUM44 cells was antiproliferative, although to a
lesser degree than heregulin (Fig. 2C). The attenuated anti-
proliferative effect of HB-EGF correlated with the lower levels
FIG. 3. Differentiation changes in SUM44 cells in response to heregulin. SUM44 cells were grown in the presence or absence of 10 ng of
heregulin b1 per ml for 1 week and photographed live (A) or after staining with Sudan IV, a neutral lipid stain (B). In the presence of heregulin,
cells become larger and flattened, with prominent vacuolization. Sudan IV staining demonstrates lipid droplet formation in heregulin-treated cells.
(C) To quantify the extent of neutral lipid production, cells were stained with a fluorescent neutral lipid stain, Nile red, and analyzed by FACS.
Treatment with heregulin induces accumulation of neutral lipids, as evidenced by a shift of the curve toward higher-intensity staining in the
heregulin (hrg)-treated cells.
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of HER4 tyrosine phosphorylation (Fig. 2B). Thus, activation
of HER4 alone correlates with an antiproliferative effect in
response to HER4 ligands. In MDA-MB-453 cells, HB-EGF
did not induce HER2 or HER4 tyrosine phosphorylation
above the baseline constitutive activation (Fig. 2B) and did not
slow growth of these cells (data not shown).
Differentiation in response to HER4 activation. Decreased
proliferation is one of the phenotypic changes that occur with
differentiation of human breast cancer cells, but decreased
proliferation may occur without differentiation. Therefore, we
looked to see whether other phenotypic changes occurred with
heregulin or HB-EGF stimulation. With differentiation, breast
epithelial cells change morphology, becoming more flattened
with higher cytoplasm-to-nucleus ratios. They produce milk
proteins, which in human cells can be measured by detecting
an increase in neutral lipids. SUM44 cells were treated with
heregulin and examined for morphologic changes and neutral
lipid production as measured by Sudan IV staining. Over a 2-
to 6-day heregulin treatment, a proportion of the SUM44 cells
underwent clear morphologic changes consistent with differ-
entiation (Fig. 3A). These and other cells without such signif-
icant morphologic changes produced neutral lipid droplets
(Fig. 3B). In order to better evaluate the percentage of cells
that underwent these differentiative changes, we quantified
neutral lipid-producing cells by fluorescence-activated cell
sorting (FACS) analysis using Nile red (Figure 3C). Heregulin
clearly induced morphologic changes and neutral lipid produc-
tion in SUM44 cells.
Attenuation of antiproliferative response to heregulin by
expression of kinase-inactive HER4. Heregulin causes tyrosine
phosphorylation of HER2 and HER3 as well as HER4 in
SUM44 cells and induces differentiation changes. HB-EGF
induces tyrosine phosphorylation of only HER4 in these cells
and induces antiproliferative changes, suggesting that HER4
alone is responsible for transmitting the antiproliferative signal
seen in response to both ligands. To further support the role of
HER4 in transmitting an antiproliferative signal, we attempted
to block the antiproliferative response to heregulin by inter-
fering with HER4 activation. A kinase-inactive HER4 con-
struct (kdHER4) that in other receptor contexts acts as a
dominant negative was created by site-directed mutagenesis
and introduced into SUM44 cells by retroviral infection. Se-
lection of kdHER4- or vector-expressing cells was performed
with the antibiotic G418. Cells expressing kdHER4 demon-
strated increased proliferation compared with vector control
cells, suggesting that kdHER4 was counteracting a growth in-
hibitory signal. In addition, expression of kinase-dead HER4
(but not vector) in SUM44 cells blocked the heregulin-depen-
dent antiproliferative response (Fig. 4A). The effects of kinase-
dead HER4 expression on HER2, HER3, and HER4 tyrosine
phosphorylation are shown in Fig. 4B. Expression of kinase-
dead HER4 did not interfere with ligand-induced HER2 or
HER3 tyrosine phosphorylation. There was an apparent in-
crease in HER4 phosphorylation, presumably due to phos-
phorylation of the kinase-dead receptor, which is expressed
at high levels. This may result from HER2-kdHER4 het-
erodimers, with the HER2 providing the kinase, as occurs with
EGF-dependent EGFR tyrosine phosphorylation of kinase-
dead HER2. Regardless, it is clear that heregulin-dependent
HER2, HER3, and HER4 tyrosine phosphorylation is insuffi-
FIG. 4. (A) Introduction of a kinase-dead HER4 construct in SUM44 cells. Full-length HER4 containing a mutation in the ATP binding
domain which renders it kinase dead (kdHER4) was expressed in SUM44 cells after retroviral infection and selection with G418 (expression was
confirmed by RT-PCR). SUM44-kdHER4 cells or vector control cells were plated at a density of 105 cells per well in six-well plates and grown
in the presence or absence of 10 ng of heregulin b1 per ml for three medium changes (7 days), and the number of cells was counted. Error bars
represent standard deviations of at least three experiments. Control cells demonstrated significant growth inhibition in response to heregulin, but
this response was attenuated in cells expressing kinase-dead HER4. (B) Ligand-induced receptor phosphorylation in vector control cells or cells
expressing kdHER4. Cells were treated with 10 ng of heregulin b1 per ml for 10 min, immunoprecipitated (IP) with HER2, HER3, or HER4,
electrophoresed, and blotted with antiphosphotyrosine (anti-PY). Expression of kinase-dead HER4 did not affect HER2 or HER3 phosphory-
lation. There was an apparent increase in HER4 phosphorylation, presumably due to endogenous phosphorylation by heterodimeric partners of
the kinase-dead receptor, which is expressed at high levels.
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cient to send the full HER4 signal in cells overexpressing
expressing kdHER4; i.e., the antiproliferation response is at-
tenuated. The explanation for attenuation of the HER4 signal
presumably lies in the lack of specific tyrosine phosphorylation
sites on HER4 phosphorylated by HER2 or, perhaps more
intriguingly, the absence of activated HER4 kinase domain-
engaging specific substrates (even soluble non-SH2 domain-
containing substrates) that trigger the antiproliferation signal;
we are currently investigating these hypotheses.
Expression of HER4 in HER4-negative cells: acquisition of
antiproliferative and differentiation capability. It is possible
that some unique characteristic of SUM44 cells resulted in the
detection of a HER4-dependent antiproliferative response.
Therefore, a second model cell system was sought. SUM102 is
a primary human breast cancer cell line that does not demon-
strate a proliferative or antiproliferative response to heregulin
(Fig. 1A), nor does it exhibit heregulin-dependent differenti-
ation (not shown). SUM102 cells do not express HER4 (Fig.
1B). Therefore, to determine whether expression of HER4 in
a HER4-negative cell line would be sufficient to induce an
antiproliferative and/or differentiation response to heregulin,
SUM102 cells were infected with retrovirus containing full-
length HER4 or vector alone and selected for neomycin resis-
tance. The resistant colonies grew slowly but yielded several
lines. Vector-infected control cells do not express HER4, while
SUM102-HER4 lines stably express HER4 that is tyrosine
phosphorylated in response to heregulin (Fig. 5). EGFR phos-
phorylation in response to EGF is unaffected by HER4 expres-
sion. SUM102 cells express very low levels of HER2 (Fig. 1C),
which is not appreciably phosphorylated in response to heregu-
lin whether or not HER4 is expressed. SUM102 cells do not
express HER3.
While neither parental SUM102 cells nor SUM102-pLXSN
vector control cells demonstrated an antiproliferative or dif-
ferentiation response to heregulin, SUM102-HER4 exhibited
slowed growth in response to heregulin (Fig. 6A). In addition,
SUM102-HER4 cells demonstrated increased neutral lipid
production when treated with heregulin, while the parental
SUM102 cells (data not shown) and SUM102-pLXSN control
cells (Fig. 6B) did not. Thus, expression of HER4 provided
SUM102 cells with both antiproliferative and differentiative
responses to heregulin, suggesting that HER4 is essential for
the differentiation response.
To further confirm that SUM102-HER4 cells were under-
going differentiation changes upon heregulin stimulation, we
evaluated the expression of E cadherin, whose expression has
been correlated with differentiation changes in a number of
systems (reviewed in reference 51). Heregulin induced a 2.5-
fold increase in expression of E cadherin in SUM102-HER4
cells but not in control cells (Fig. 6C), and this was quantified
by densitometry (Fig. 6D). Thus, heregulin induces an antipro-
liferative response only in SUM102 cells that express HER4.
The antiproliferative response is paralleled by differentiation
changes, including neutral lipid production and increased E
cadherin expression.
Removal of HER2 does not abolish the heregulin-dependent
antiproliferative response. Our results in both cell lines sug-
gested that HER4 plays a necessary role in mediating an
antiproliferative and differentiation signal, but they do not
answer a central question; does HER2 contribute to this re-
sponse? To determine this, the capacity for HER2 signaling
was removed from both SUM44 and SUM102-HER4 cells by
abolishing HER2 cell surface expression. This was accom-
plished by sequestering HER2 in the ER by expressing single-
chain anti-HER2 antibody containing an ER-targeting se-
quence (19). This cDNA construct, 5R, was introduced into
cells after having been packaged as an amphotrophic retrovi-
rus. Selection of infected SUM102-pLXSN, SUM102-HER4,
and SUM44 cells by puromycin resistance resulted in cell lines
expressing 5R in addition to HER4. This resulted in a loss of
membrane-localized HER2, as determined by immunohisto-
chemistry (data not shown), and completely abolished heregu-
lin-dependent HER2 tyrosine phosphorylation (Fig. 7A). Con-
sistent with reports that expression of 5R can reduce
heregulin-induced HER4 phosphorylation (4), there was a re-
duction in heregulin-induced HER4 tyrosine phosphorylation
in SUM44 cells. The HER2 single-chain ER-tagged antibody
also virtually abolished heregulin-induced HER3 phosphory-
lation in SUM44 cells. In SUM102-HER4 cells, expression of
the 5R construct did not appreciably dampen phosphorylation
of the exogenously expressed HER4 (Fig. 7B), possibly be-
cause this HER4 is expressed at high levels compared with the
endogenous levels of HER4 seen in SUM44 cells, and there is
essentially no detectable HER2 activation in the parental line
(Fig. 5). The 5R construct did not affect the ability of EGF to
induce phosphorylation of EGFR. SUM102 cells do not dem-
FIG. 5. Stably infected SUM102 cells express HER4 that is acti-
vated by heregulin. Full-length HER4 was stably expressed in SUM102
cells, a HER4-negative human breast cancer cell line, by retroviral
infection and selection for G418 resistance. HER4 expression was
confirmed by Western blotting using HER4 antiserum. Vector expres-
sion was confirmed in control cells by RT-PCR of neomycin-resistant
cells (data not shown). Tyrosine phosphorylation of HER4 and HER2
in response to heregulin stimulation was measured by immunoprecipi-
tation (IP) with antibody to HER4 or HER2 and Western blotting with
antiphosphotyrosine (anti-PY). Phosphorylation of EGFR in response
to EGF stimulation was similarly examined. In SUM102-HER4 lines,
HER4 is not constitutively activated but is activated in response to
ligand. There is no appreciable phosphorylation of HER2 in either
HER4-expressing or wild-type cells, and EGFR phosphorylation in
response to EGF is not altered by HER4 expression.
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FIG. 6. SUM102 antiproliferative and differentiative response to heregulin with and without HER4. (A) Antiproliferative response. SUM102-
HER4 or vector control cells were plated at a density of 5 3 105 cells per well in six-well plates and grown in the presence or absence of 10 ng
of heregulin b1 per ml for three medium changes (7 days), and the number of cells was counted. The ratio of number of cells grown in the presence
versus the absence of ligand is shown. Error bars represent standard deviations of at least three experiments. SUM102-HER4 cells are growth
inhibited with heregulin, to an extent comparable to that of SUM44 cells. Wild-type (Fig. 1A) and vector control SUM102 cells do not have an
antiproliferative response to HER4. (B) Neutral lipid production. SUM102 cells expressing vector or HER4 were treated with 10 ng of heregulin
per ml for 4 to 6 days and stained with Nile red. The intensity of staining was measured by flow cytometry, and histograms of control and
heregulin-treated cells were overlaid. SUM102-HER4 cells have increased neutral lipid staining when treated with heregulin, comparable to
SUM44 cells, while HER4-negative control cells do not. (C and D) E cadherin expression. (C) SUM102-pLXSN vector control cells or
SUM102-HER4 cells were treated with 10 ng of heregulin per ml for 4 to 6 days and lysed, and Western blotting was performed with anti-E
cadherin antibody. (D) Densitometry of E cadherin expression by Western blot. Values are intensities (fold), and standard deviations of at least
three experiments are shown by the error bars. SUM102-HER4 but not SUM102-pLXSN demonstrated increased E cadherin expression in
response to heregulin.
4272
onstrate appreciable HER2 phosphorylation in response to
heregulin (Fig. 5) or express HER3 (Fig. 1C).
SUM44 cells expressing the pBABE vector exhibited both
HB-EGF- and heregulin-dependent antiproliferative responses.
Again, heregulin was more potent. Introduction of 5R and
elimination of HER2 signaling did not block either ligand-
dependent antiproliferative response in SUM44 cells (Fig. 7C).
In the SUM102-pLXSN cells, which do not express HER4,
sequestration of HER2 did not change the lack of antipro-
liferative response to heregulin (Fig. 7D). Furthermore, in
SUM102-HER4 cells, which had acquired an antiproliferative
response to heregulin by virtue of HER4 expression, seques-
tration of HER2 did not abolish this response. Thus, unlike
HER4, HER2 is not necessary for the antiproliferative re-
sponse in cells with either endogenous (SUM44) or exog-
enously expressed (SUM102-HER4) HER4.
DISCUSSION
In our studies of HER4 in human breast cancer cells, we
found clear antiproliferative and differentiative responses to
heregulin in SUM44 cells. This response correlated with
heregulin-induced HER4 tyrosine phosphorylation and was
induced by another HER4 ligand, HB-EGF, which activates
HER4 but not the other EGFR family members in this cell
line. In addition, overexpression of kinase-dead HER4 oblit-
erated this response. The only other cell lines that demon-
strated growth suppression upon treatment with heregulin,
FIG. 7. The antiproliferative effect of heregulin persists even after removal of HER2 signaling. SUM44 cells and SUM102-pLXSN or
SUM102-HER4 cells were infected with retrovirus containing vector alone or containing the anti-HER2 ER-tagged single-chain antibody 5R. After
selection in G418, removal of HER2 from the membrane by 5R was confirmed by immunohistochemistry, demonstrating loss of HER2 membrane
immunoreactivity in both (SUM44 and SUM102) 5R-containing lines (data not shown). (A) Tyrosine phosphorylation of HER2-4 in response to
heregulin in SUM44 derivatives. Cells containing the 5R construct did not demonstrate heregulin-dependent HER2 tyrosine phosphorylation, as
opposed to vector control cells, indicating that 5R effectively eliminates HER2 signaling in these cells. The 5R construct also inhibited
heregulin-induced HER3 phosphorylation and dampened HER4 phosphorylation. IP, immunoprecipitation; anti-PY, antiphosphotyrosine. (B)
Tyrosine phosphorylation of HER4 and EGFR in response to ligand stimulation in SUM102 derivatives. The 5R construct did not affect HER4
or EGFR ligand-induced phosphorylation. (C) Antiproliferative response of SUM44-5R cells. SUM44 vector control pBABE and 5R expressing
cells were treated with heregulin or HB-EGF, and the proliferative response was measured as described in Materials and Methods and for Fig.
1. The absence of HER2 signaling did not alter the growth inhibitory responses of heregulin and HB-EGF. (D) Antiproliferative response to
SUM102-HER4 cells. SUM102-HER4 cells or vector control cells containing 5R were treated with heregulin. Sequestration of HER2 and removal
of HER2 tyrosine phosphorylation did not abolish the antiproliferative effect, and SUM102-5R cells which do not contain HER4 did not
demonstrate an antiproliferative effect.
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SUM185 and SUM225, also exhibited HER4 expression.
HER4-negative cells did not show a heregulin-dependent an-
tiproliferative response. To further confirm the involvement of
HER4 in mediating an antiproliferative and differentiative re-
sponse, we expressed HER4 in HER4-negative SUM102 cells.
HER4-expressing SUM102 cells acquired an antiproliferative
and differentiative response upon HER4 activation. Thus,
HER4 can mediate antiproliferative and differentiative signals
in human breast cancer cells.
Activation of HER4 and HER2 has been associated with a
range of responses, including growth stimulation and suppres-
sion, as well as stimulation of expression of differentiation
markers. The outcome depends upon the cell type, the com-
plement of EGFR family members expressed, the level of
HER2 expression, the ligand (and even the ligand isoform),
and the presence of other growth factors or serum. Our aim
was to specifically investigate the role of HER4 in the antipro-
liferative and/or differentiative response and to prove, to the
extent possible, that HER4 activation alone was necessary and
or sufficient to produce this response.
We hypothesized that if any EGFR family member was
primarily responsible for the antiproliferative and differentia-
tive response, HER4 was the likely candidate, since HER4 has
been implicated in differentiation developmental responses in
a number of settings. In the endometrium, HER4 expression
and expression of HER4 ligands are increased during the se-
cretory phase, suggesting a role in endometrial maturation
(46). HER4 is critical for cardiac and neural development, as
HER4 knockout mice are nonviable due to impaired cardiac
and neural development (6, 18). In the mouse mammary gland,
a carboxy-terminal deletion mutation of HER4 impairs post-
partum lobuloalveolar development due to a lack of terminal
differentiation (24). Consistent with a role in antiproliferation
and differentiation, in human breast cancers HER4 expression
is associated with low histological grade (47). This is in contrast
to HER2, which is often associated with tumors with poorer
prognostic features and outcome.
The complicated nature of EGFR family member interac-
tions makes it difficult to discern the contribution of each
member to the differentiation response. For example, the dif-
ferentiation response to heregulin has alternately been attrib-
uted to HER2 and HER4, since heregulin can activate both
receptors. We first implicated HER4 by using a ligand, HB-
EGF, that does not activate HER2. To more definitely elimi-
nate the contribution of HER2, we used single-chain antibod-
ies that sequester HER2 in the ER. The antiproliferative
response to heregulin was not abolished with HER2 loss. Our
studies demonstrate that HER4 can mediate an antiprolifera-
tive signal but do not rule out a contribution from HER2 to a
differentiative signal. This is consistent with the findings of
others. In MCF7 cells, removal of surface HER2 affected
heregulin-induced morphologic differentiation changes. How-
ever, HER2 was not required for heregulin effects on prolif-
eration (4). Antisense HER2 expressed in AU565 cells caused
cells to proliferate more slowly and abolished the antiprolif-
erative and differentiation response to high concentrations of
heregulin without affecting the proliferative response to low
concentrations of heregulin (55). In AU565 cells, HER2 inhib-
itory antibodies induce differentiation, suggesting that removal
of HER2 may enable a HER4 differentiation signal to predom-
inate (3). HER4 agonist antibodies can induce a differentiation
response, which is partially reversed by HER4 antagonist an-
tibodies, but this is also seen with HER2 (9).
However, some studies of EGFR family member activation
in 32D mouse myeloid cells support a proliferative function for
HER4, since cells expressing HER4 alone or in combination
with EGFR demonstrated a mitogenic response to stimulation
with EGF or epiregulin (43, 49). Furthermore, downregulation
of exogenously expressed HER4 by ribozymes decreased pro-
liferation, suggesting that HER4 was mediating proliferative as
opposed to antiproliferative or differentiative responses (48).
However, others found that 32D cells expressing both HER2
and HER4 were growth stimulated by HB-EGF, whereas those
expressing only HER4 had a growth inhibitory response, sug-
gesting that HER4 may be involved in proliferative or anti-
proliferative signals, depending on presence of HER2 (52).
Similarly, we have found that activation of an EGFR-HER4
chimera induced an antiproliferative response in 32D cells
(data not shown).
Our studies conclusively support a role for HER4, in the
absence of HER2, as a mediator of an antiproliferative and
differentiative response in human breast cancer cell lines. Fur-
ther investigations are under way to determine the downstream
signal transduction pathways involved in HER4 signaling.
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